BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for AN2 Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 4:29 pm Sale | 2024-09-30 | 13G | AN2 Therapeutics, Inc. ANTX | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -1,563,963 (Position Closed) | Filing |
| 2023-02-14 11:45 am Sale | 2022-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | BIOTECHNOLOGY VALUE FUND L P | 1,563,963 8.100% | -52,702 (-3.26%) | Filing |
| 2022-04-04 4:38 pm Purchase | 2022-03-25 | 13G | AN2 Therapeutics, Inc. ANTX | BIOTECHNOLOGY VALUE FUND L P | 1,616,665 8.600% | 1,616,665 (New Position) | Filing |